Merck's c-Met inhibitor is declared for listing in China, Jiangsu Hansoh, Haihe Pharmaceutical are multi-enterprise layout, is there any chance for latecomers
Time of Update: 2022-04-27
The marketing application of tepotinib hydrochloride was accepted, source: CDE official website Tepotinib (tepotinib, trade name Tepmetko) is an oral c-MET inhibitor that has been approved for marketing in Japan and the United States for the treatment of Non-small cell lung cancer (NSCLC) patients with MET exon 14 (MET ex14) skipping .
Express aims to cure diabetes, CRISPR-edited cell replacement therapy enters the clinic
Time of Update: 2021-12-07
▎ WuXi AppTec content team editor November 16, 2021, ViaCyte and CRISPR Therapeutics jointly announced that Health Canada has approved a clinical trial application (CTA) for CRISPR gene-edited stem cell-derived therapy VCTX210 for the treatment of type 1 diabetes (T1D) ) .
Turn tumor-related macrophages back into cancer fighters
Time of Update: 2021-08-27
The up-regulation of STAT6 activity also leads to increased expression of genes that transform metabolism to fatty acid oxidation, for M2 macrophages with high metabolic demands .
-20-1723Hedgehog signaling regulates metabolism and polarization of mammary tumor2 associated macrophages
The role of the key gene Mesp1 in the earliest stages of cardiovascular cell lineage separation
Time of Update: 2020-08-13
Fabienne Lescroart and his colleagues isolated the cells expressing Mesp1 at different stages of embryonic development and performed a single-cell transcription group analysis of these early cardiac progeny cells to identify the molecular characteristics associated with the region and cell type identity of the heart's progeny cells.
Optimising treatment options for cancer patients NTRK gene fusion detection obtains breakthrough medical device identification
Time of Update: 2020-06-17
ArcherDX focuses on tackling bottlenecks in the second-generation sequencing of tumor mutation genes Its proprietary and powerful target gene sequencing platform uses proprietary chemical reagents to
Top 5 drugs with patent expiration in 2019: Roche exclusive 3
Time of Update: 2019-01-23
Patent expiration is a problem that all successful pharmaceutical companies have to face in the end, and Roche, the Swiss pharmaceutical giant, will face a particularly dangerous year in this regard I